Binary Views
Oncology
Oncology
Anatomy Rules All!
Symptoms? Handmaidens


Adopt concept

Biology (Symptoms) key as anatomy

Suffering

Tumour Progress

Factors driving tumor and symptoms



Reinforcement ... Common Endpoints

Acute Inflammation

- Innate Immune System
 - Wound healing
 - Tissue repair
 - Angiogenesis

- Adaptive Immune System
 - Specific response to antigen
 - Cytotoxic T cells


Chronic Inflammation

• Innate

Promote tumour growth and spread

Adaptive

Reduced NK cell activity



Advancing Cancers

Infiltrating → TAM TIL

Crowth Footors | Turnour Imm

Growth Factors
Angiogenesis
Proteases – matrix

Tumour ImmunityTh2 ↑ Th1 ↓

We suggest that the inflammatory cells and cytokines found in tumours are more likely to contribute to tumour growth, progression and immunosuppression than they are to mount an effective host anti-tumour response... some types of inflammation may provide 'the fuel that feeds the flames'.

Balkwill, Mantovani. Lancet. February 17, 2001

Immune cells regulating tumor growth

Stimulate Cancer Growth

Inhibit Cancer Growth

Innate immune cells

neutrophils

macrophage (M1)

macrophage (M2)

myeloid-derived suppressor

cells

Adaptive immune cells

Th2 CD4⁺T cell

Cytotoxic CD8⁺ T cell

CD4⁺ T regulatory cell

Th1 CD4+ T cell

B lymphocytes

TH17 CD4⁺ T cell

ACS - Cytokines

Not helpful

Int. 1 – B

IL - 8

Helpful?

IL - 12

IL - 15

IL - 24

Both ways:

IL-6


IL - 10

IL-17

 $TNF\alpha$

"Taoist – not linear"

TUMOUR




CRP - Prognosis

- Ovarian
- Lung
- Melanoma
- Pancreas
- Stomach
- Head and Neck
 Resectable Tumours colorectal, upper GI,

renal, bladder

Median survival by CRP Trajectory

	Median survival (months)	95% CI
Normal ⇒ Normal	21.6	11.9-31.6
Normal ⇒ Abnormal	12.3	6.5-18.1
Abnormal ⇒ Normal	10.7	7.6-13.5
Abnormal ⇒ Abnormal	8.3	7.0-9.5
Log Rank (Mantel-Cox)<0.001		



Inflammation Immuno-neuroendocrine aberrations


- 1. ↑ CRF cortisol
 2. ↑ sympathetic activity
 - Cytokine activity
 - Pulse -REE
 - Psychosocial stress
 - testosterone
 - Hypogonadism sex drive activity

Stress

Mechanisms:

cancer initiation
tumor growth
angiogenesis
metastases
reduce apoptosis
reduce TH₁ AND lymphocytes

Armaiz-Pena et al Brain behavior and immunity 2009; 23:10-15



Riley Vernon. Mouse Mammary Tumors: Alteration of Incidence as Apparent Function of Stress. Science 1975:189:465.

Stress

Animal Data

- Riley.....Tumor Growth
- Sloan et al.....Metastases

Chronic stress mouse model 30 x metastases

Blocked by propranolol

Sloan et al. CancerRes2010;70:1042

Stress

Basic data

Ben Eliyahu.....Survival

Mouse tumor models
Post surgery

Etodolac and Propanolol

Lee et al......Human Ovarian nude mice

Reiche et al.....Stress hormone

Switch from Th1 to Th2 immune response

Propranolol

A Human Rodent

- 1. Elderly
- 2. Small Tumour Mass
- 3. Chronic Inflammatory State
- 4. REE up
- 5. Both Anorexia and Cachexia
- 6. Fatigued low function
- 7. On chemotherapy/opioids
- 8. Gender balance

Stress – human correlation

Childhood stress - chronic disease risk

Social deprivation – ovarian cancer (lutgendorf)

_ colorectal cancer (McMillan)

Correlation with immune neuroendocrine change

"Collective evidence points to a prominent role for chronic stress in cancer growth and metastasis"

Moreno-Smith M. et al *Impact of stress on cancer metastasis*. Future Oncology Dec2010

Stress - human correlation

Breast cancer.....Spiegel

Anderson

GI cancer....Kuchler

Melanoma.....Fawzy

Programs

Cognitive/Behavioural

Mindfulness

Supportive

Exercise - Yoga

Correlations with immuno endocrine change


Biobehavioral influences on cancer progression Costanzo et al. *Immun-al Clin NA* 2011;109:32

Propranolol - Atenolol

Effects on β adrenergic blockade
 Breast cancer

- Melhem-Bertrandt A, Chavez-MacGregor M, Lei X et al. Beta-blocker use is associated with improved relapse-free survival in patients with triplenegative breast cancer. J Clin Oncol doi: 10.1200/JC0.2010.33.4441.
 - Barron TI, Connolly RM, Sharp L et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol doi: 10.1200/JCO.2010.33.5422.

Correlation Between CRP and Severity of Symptoms Reported by Patients



Sleep - Inflammation

- Acute
 - Deprivation CRP Il-6 Il- 1β
 - Inflammation -
 - Poor sleep quality
 - Insomnia
 - Fatigue
- Bidirectional vicious circle

• Simpson et al *Nutrition Reviews* Dec 2007

Pain - Inflammation

Animal Studies

ll-6 -- pain models

Il-6 KO -- ↓ pain response

Interference -- opioid response

Human Studies

 \uparrow Il-6, TNF α , Il – 1 β – Regional CSF (neuropathic pain)

Cancer

Laird et al: Trial 1 CRP Trial 2

275 patients 174 patients


0.036 0.032


0.126 (Pearson) 0.163

Pain2011;152:460-463

Cancer Cachexia - Anorexia







Metabolic changes in tumor related weight loss

- insulin resistance
- diminished lipogenesis
- increased lipolysis
- increased protein synthesis liver
- muscle synthesis proteolysis acute phase protein response CRP
- inflammatory cytokines
- Il-1 β , Il-6, other Th₂ cytokines)
- TREE

Anorexia-cachexia

PERIPHERAL

- Inflammation cytokines, eicosanoids
- Muscle loss
- Hypercatabolism dysautonomia
- Hypogonadism
- Oxidative Stress
- Activin?
- Genetic Predisposition
- Tumor Factors

CENTRAL

Hypothalamus Cerebral STN influence

Chronic Inflammation - Cancer

- Immune response often facilitates tumor progress
- Tumor cells produce inflammatory chemical mediators assisting growth
- Inflammatory mediators enhance many cancer symptoms
- Early evidence anti-inflammatory agents may modify the course of cancer
- Will anti-inflammatory (palliative) therapies improve life quality and quantity?
- Relief of cachexia survival?

Palliative Care-improve outcomes?

Quality of life --- Seven studies
 Yes - 5/7

- Symptoms --- Fifteen studies
 - "overall the results of these 15 studies provide little evidence to support the efficacy of palliative care interventions in alleviating physical symptoms" -

WHO Definition Palliative Care - 2002

"Palliative care is an approach which improves the quality of life of patients facing the problems associated with lifethreatening illness, through prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual."

The McGill Cancer Nutrition-Rehabilitation Program



CNR Interdisciplinary Team MUHC-RVH



PHYSICIAN
ONCOLOGISTS
Medical Intervention

PHYSIOTHERAPIST Functional Evaluation and Rehabilitation PATIENT AND FAMILY DIETITIAN
Nutritional Evaluation
and Recommendations


NURSING, PSYCHOLOGIST, OCCUPATIONAL THERAPIST, SOCIAL WORKER





Conceptual model of cancer trajectory





Barb Tarbox 1961 - 2003

Workup

- Questionnaires
 - ESAS
 - Distress
 - PG-SGA
 - •CHAMPS
- CRP
- WBC
- Testosterone bioavailable
- Thyroid


Rehab Tests

- Tests (endurance, strength, ROM, balance)
 - 6MW, Gait, Balance
 - CHAMPS (general activities all types)- fatigue
 - Sit to stand
 - Gait speed
 - Review safety


Program

- 8 10 weeks with clear initial and end evaluation
- Nutritional counselling
- Basic intervention= physio 1-2 times /week
- 1 visit / 2 weeks other team members
- Caregiver information
- Weekly psycho-education groups meet once /week x 9 rotating sessions

Changes in ESAS Scores after 8-week CNR program for Patients with Advanced Cancer presenting with CRP < 12 at Initial CNR Evaluation (N = 95)




Initial and Final Total ESAS Scores for Patients with Advanced Cancer presenting with CRP < 12 or CRP ≥ 12 at Initial CNR Evaluation (N = 103)




^{*} *p* < 0.05 vs. Initial


Percentage of Patients with Advanced Cancer who Lost, Maintained or Gained Weight during the CNR program by Inflammatory Status (N = 114)



Initial and Final ESAS Anorexia Scores for Patients with Advanced Cancer presenting with CRP < 12 or CRP ≥ 12 at Initial CNR Evaluations (N = 117)



Percentage of Patients with Advanced Cancer with Taste &/or Smell Alterations at Initial and Final CNR Evaluations (N = 103)



^{*} p < 0.05 vs. Initial; † p < 0.05 vs. CRP < 12

Evaluation


- High patient satisfaction
- Advanced cancer patients can exercise
- CRP status determines completion of an exercise program
- Measured improvements in appetite, weight and function

Multimodal program

Is our program anti-inflammatory?

- 1. Dietary advice yes
- 2. Exercise yes
- 3. Psychosocial component yes
- 4. Drugs not really

Note – no overall change in CRP status



NO reduction cytokines
Reduction tumor growth
BUT muscle mass survival

Drugs - Cachexia

- Re-examine Omega 3's/NSAIDs
- Selective androgen receptor modifiers (SARMS)
- β agonists formoterol
- B agonists propanolol
- Cytokine inhibitors anti Il-6
- Activin myostatin reversal




Figure 3. Kaplan-Meier Estimates of Survival According to Study Group.

Palliative Care – what we do

- 1. Identify manage psychosocial issues
- 2. Emphasis on caregiver support
- 3. Relief of physical causes of suffering
- 4. Focus on Nutrition
- 5. Focus on muscle function and rehabilitation

Hypothesis –

Palliative Care interventions may impact on patient survival as well as Q/L

Animal data is sufficient to support this hypothesis. Human data is very modest but compelling.

Palliative Care – what we do

- 1. Identify manage psychosocial issues
- 2. Emphasis on caregiver support
- 3. Relief of physical causes of suffering
- 4. Focus on Nutrition
- 5. Focus on muscle function and rehabilitation

If true the importance to cancer patients is major and must lead to prioritizing integrated palliative care/chemo-bio trials.

A substantive change in both oncology thinking and trial structure is required. We must study whole care packages <u>not</u> simply drugs.

Ethical Issues – Trial Research

- Priorities
 - Set for patient interest?
 - Drug costs
 - Low probability trials
 - 'me too' trials
- Patient's best interest
 - Business interests
 - Price per patient
 - Locale
 - Investigator CI

You are not eligible if you are taking part in another trial

Fastidious vs Pragmatic trials

Fastidious vs Pragmatic Trials

 Fastidious Trials – 'using homogeneous groups, reducing or eliminating ambiguity'

 Pragmatic Trials – 'would incorporate heterogeneity, ambiguity, and other messy aspects of clinical practice'

Feinstein – Ann Int Med 1983

Ideal Trial - I

- Pragmatic reflecting practice
- Reflect multifactorial nature
- Wide application
- Newly diagnosed patients

Ideal Trial - II

- Patients 1st Line
 - True 'Best Supportive Care'
 - Symptom Control
 - Nutrition and Exercise
 - Palliative care involvement
- Chemobiotherapy vs chemobiotherapy
 - SARMS
 - anti-inflammatory agent
 - anti-myostatins
- Stratify by CRP

MENAC Trial - EAPC Research Network

Stratifyadvanced lung, pancreas, colorectal

Standard Palliative Care

Nutrition – counseling – HMB&EPA

Exercise

Drug - Celecoxib

Stratify - Weight Loss - CRP - Chemotherapy

Courtesy Stein Kaasa

Improving Symptom Research

- 1. Change in mind set. Symptoms reflect tumour activity and are probably as important as partial anatomic change in tumour mass.
- 2. Change trial priority.
 - Curative trials
 - Pragmatic trials care package
 - Fastidious trials limited studies on drugs with limited inclusion/exclusion clauses
 - 'Me too' trials

Proposals

- 1. Engage Binary Vision
- 2. Collaborative Group
 - international
- 3. Funding
 - public
 - probonum? industry, philanthropic
- 4. End Points
 - quality of life
 - Function
 - survival

Upon this gifted age, in its dark hour,
Rains from the sky a meteoric shower
Of facts...they lie unquestioned, uncombined.
Wisdom enough to leech us of our ill
Is daily spun, but there exists no loom
To weave it into fabric

Edna St Vincent Millay